Agenda
This program has been accredited for one hour of CME credit.
17:35 GMT
Marc-Andrea Bärtsch
BCMA-directed therapies in multiple myeloma: Current applications and the evolving clinical landscape
17:55 GMT
Hermann Einsele, Marc-Andrea Bärtsch, Gordon Cook, and María-Victoria Mateos
Panel discussion | Practical considerations when sequencing novel agents and managing adverse events with BCMA-directed therapies
18:15 GMT
María-Victoria Mateos
Future directions with novel and established BCMA-directed therapies in the multiple myeloma treatment paradigm
Following the close of the symposium, there will be an optional 'Virtual exhibitor space' session with the symposium speakers and GSK representatives as an opportunity for further discussion and networking.
Learning objectives
Following the symposium, learners will be able to:
- Describe the mechanisms of action of different BCMA-directed therapies for the treatment of multiple myeloma.
- Recall key clinical trials and real-world evidence supporting the use of BCMA-directed therapies in multiple myeloma.
- Recall key considerations for patient selection, eligibility, and sequencing of BCMA-directed therapies.
- Describe strategies to overcome mechanisms of resistance to BCMA-directed therapies, including options for retreatment.
- Describe strategies to manage common toxicities associated with BCMA-directed therapies and optimize patient quality of life.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy